UBS Remains a Buy on Novo Nordisk (0QIU)
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan
JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
Sky14d
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...
KSTP-TV14d
AG Ellison announces settlement in lawsuit against insulin manufacturer Novo Nordisk
Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo Nordisk. Minnesota residents will now be able to get Novo Nordisk insulin ...
Fox 914d
MN Novo Nordisk settlement over insulin pricing [RAW]
MN Novo Nordisk settlement over insulin pricing [RAW] Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires ...
ENDPOINTS NEWS19d
GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?
A new study found that pa­tients tak­ing GLP-1s to treat type 2 di­a­betes have a low­er risk of de­vel­op­ing Alzheimer’s dis­ease, po­ten­tial­ly open­ing the door … ...
Outsourcing-pharma20d
Novo Nordisk reports positive results for high-dose Wegovy formulation
Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...
Fortune21d
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
clinicaltrialsarena21d
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...
BioSpace21d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Insider Monkey23d
Why Did Novo Nordisk (NVO) Go Down on Friday?
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green ...
The Motley Fool23d
Is Novo Nordisk Stock a Buy?
Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.